HST Global Competitors

HST Global (OTCMKTS:HSTC) and Intellipharmaceutics International (OTCMKTS:IPCIF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares HST Global and Intellipharmaceutics International's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares HST Global and Intellipharmaceutics International's top-line revenue, earnings per share and valuation.

HST Global has higher earnings, but lower revenue than Intellipharmaceutics International.

Analyst Ratings

This is a summary of recent recommendations and price targets for HST Global and Intellipharmaceutics International, as reported by MarketBeat.

Volatility and Risk

HST Global has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500. Comparatively, Intellipharmaceutics International has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.

Summary

Intellipharmaceutics International beats HST Global on 4 of the 6 factors compared between the two stocks.

HST Global (OTCMKTS:HSTC) and BriaCell Therapeutics (OTCMKTS:BCTXF) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Institutional and Insider Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. 65.8% of HST Global shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares HST Global and BriaCell Therapeutics' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares HST Global and BriaCell Therapeutics' top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for HST Global and BriaCell Therapeutics, as reported by MarketBeat.

Volatility & Risk

HST Global has a beta of -0.52, indicating that its share price is 152% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.

Summary

BriaCell Therapeutics beats HST Global on 4 of the 6 factors compared between the two stocks.

HST Global (OTCMKTS:HSTC) and FutureWorld (OTCMKTS:FWDG) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Profitability

This table compares HST Global and FutureWorld's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares HST Global and FutureWorld's top-line revenue, earnings per share and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for HST Global and FutureWorld, as reported by MarketBeat.

Volatility and Risk

HST Global has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500. Comparatively, FutureWorld has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.

Summary

FutureWorld beats HST Global on 3 of the 3 factors compared between the two stocks.

HST Global (OTCMKTS:HSTC) and International Stem Cell (OTCMKTS:ISCO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations and price targets for HST Global and International Stem Cell, as reported by MarketBeat.

Volatility and Risk

HST Global has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500. Comparatively, International Stem Cell has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.

Earnings & Valuation

This table compares HST Global and International Stem Cell's top-line revenue, earnings per share and valuation.

HST Global has higher earnings, but lower revenue than International Stem Cell.

Profitability

This table compares HST Global and International Stem Cell's net margins, return on equity and return on assets.

Summary

International Stem Cell beats HST Global on 4 of the 6 factors compared between the two stocks.

Amarantus BioScience (OTCMKTS:AMBS) and HST Global (OTCMKTS:HSTC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Amarantus BioScience and HST Global, as reported by MarketBeat.com.

Valuation and Earnings

This table compares Amarantus BioScience and HST Global's top-line revenue, earnings per share (EPS) and valuation.

Risk and Volatility

Amarantus BioScience has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, HST Global has a beta of -0.52, indicating that its share price is 152% less volatile than the S&P 500.

Insider and Institutional Ownership

0.0% of Amarantus BioScience shares are owned by institutional investors. 10.3% of Amarantus BioScience shares are owned by company insiders. Comparatively, 65.8% of HST Global shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Amarantus BioScience and HST Global's net margins, return on equity and return on assets.

Summary

Amarantus BioScience beats HST Global on 4 of the 5 factors compared between the two stocks.

HST Global (OTCMKTS:HSTC) and Akorn (OTCMKTS:AKRXQ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations and price targets for HST Global and Akorn, as provided by MarketBeat.com.

Valuation and Earnings

This table compares HST Global and Akorn's gross revenue, earnings per share and valuation.

HST Global has higher earnings, but lower revenue than Akorn.

Risk and Volatility

HST Global has a beta of -0.52, suggesting that its stock price is 152% less volatile than the S&P 500. Comparatively, Akorn has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.

Institutional & Insider Ownership

0.1% of Akorn shares are owned by institutional investors. 65.8% of HST Global shares are owned by insiders. Comparatively, 3.9% of Akorn shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares HST Global and Akorn's net margins, return on equity and return on assets.

Summary

Akorn beats HST Global on 5 of the 8 factors compared between the two stocks.